Extended survival curves (>60 months) for patients with AI at chromosome 13q14.

<p>The survival curves between patients with and without AI begin to separate only after 60 months (P = 0.0159), suggesting that alteration of 13q14 is associated with long-term mortality.</p

Survival curves of six chromosomal regions associated with significant differences in survival between patients with and without AI.

<p>Red circles = tumors demonstrating AI, blue squares = tumors without detectable AI. For chromosome 16q22–q24, those patients with AI at chromosome 16q22–q24 have significantly better survival than those with retention of chromosome 16q22–q24.</p

Clinical and pathological features of 123 invasive breast tumor specimens.

<p>P-values listed as NS (not significant) >0.05.</p>a<p>Other included histological types including tubular, medullary, apocrine, and mucinous carcinomas.</p>b<p>IHC markers were used as surrogates to define subtype as follows: luminal A = ER and/or PR+/HER2−; luminal B = ER and/or PR+/HER2+; HER2-enriched = ER and PR−/HER2+ and triple negative = ER, PR and HER2−.</p

Scatter plot of levels of AI by chromosomal region.

<p>Chromosomal regions are on the x-axis, average level of AI on the y-axis. Chromosomes with significantly different frequencies between DOD and DFS groups are boxed.</p